





Juno Ther: summary of recent CAR-T/IO business alliances/deals\$

| Company | Partner | Date | Area | Details |
|---|--|-----------------------------|---|---|
|  | Memorial Sloan Kettering/Eureka | 4 th August 2016 | Novel BCMA [^] binding domain Undisclosed targets for CAR in multiple myeloma | MSK and Eureka to receive undisclosed upfront payments and milestones |
|  | JW Biotechnology (Shanghai) | 7 th April 2016 | Formation of new company leveraging WuXi AppTec's R&D and manufacturing platform. CAR and TCR-based | Equal initial ownership. Juno to receive an upfront payment in equity, milestone and royalties |
|  | Celgene | 29 th June 2015 | Broad strategic collaboration for CAR-T and TCR technologies incl CD19, CD22 and B-Cell maturation antigen | Upfront: \$150m Juno: R&D and commercial rights in North America Celgene: ROW* Other co-dev and co- promotion rights, stock purchase |
|  | Editas Medicine | 27 th May 2015 | Use of Editas CRISPR/Casg genome editing technologies to produce next generation CAR and TCR technologies | Juno to pay \$25m upfront and up to \$22m in research support. Editas also could receive milestones >\$230m for each program |

*ROW = rest of world
[^] B-cell maturation antigen
 \$ not an exhaustive list

IO = immuno-oncology

About iOnco Analytics:

iOnco Analytics is a subdivision of VacZine Analytics, a world leading supplier of vaccine market analyses

With our product lines:

- ① MarketVIEW
- ① ExpertREACT


Our role is to define market potential and strategy of new cancer immunotherapies

Disclaimer

All rights reserved

This licensed product (or part thereof) may not be reproduced, stored in a retrieval system or transmitted in any form without the written permission of the publisher VacZine Analytics (a division of Assay Advantage Ltd).

The facts presented within this document, at the time of its production, were believed to be correct and were gathered in good faith from both primary and secondary sources. VacZine Analytics is not always in the position to assure that the facts are guaranteed. VacZine Analytics cannot be held liable for any actions based upon facts or recommendations presented within this document.





iOnco Analytics

Immunotherapeutic market strategy...

www.iOnco-analytics.com

Carlton House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
Tel +44 (0) 1279 813155
E-mail: info@ionco-analytics.com